Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.50
Bid: 95.00
Ask: 102.00
Change: -2.50 (-2.48%)
Spread: 7.00 (7.368%)
Open: 101.00
High: 101.00
Low: 98.50
Prev. Close: 101.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans

Tue, 29th Aug 2023 10:23

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Pantheon Resources PLC, up 13% at 15.31p, 12-month range 10.10p-136.00p. The oil and gas company focused on onshore operations in the US receives independent expert report. It says the report provides an estimate of contingent resources recoverable from its 100% working interest Kodiak project, formerly known as Theta West. The company adds that the report confirms best estimate contingent resource estimates totalling 962 million barrels for Kodiak Field. Chief Executive Officer Jay Cheatham says: "This really is a big deal. A credible third-party estimate of nearly one billion barrels of recoverable liquids for a company the size of Pantheon is an incredible achievement, validating our geological model."

----------

Faron Pharmaceuticals Ltd, up 11% at 299.80p, 12-month range 155.00p-395.00p. The clinical-stage biopharmaceutical company says that the US Food & Drug Administration has granted orphan drug designation to its wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia. Orphan drug designation gives intellectual property cover and data protection to investigational drugs, as well as potential tax credits on eventual US sales of an approved orphan drug. Bexmarilimab is an immunotherapy designed to overcome resistance to existing treatments for acute myeloid leukaemia, a type of cancer, and myelodysplastic syndromes. "Receiving Orphan Drug Designation from the FDA signifies our continued progress and commitment to develop bexmarilimab as a potential treatment for AML," says Chief Medical Officer Marie-Louise Fjallskog. Also reports no revenue in the first half of 2023, unchanged year-on-year. Pretax loss widens to EUR13.7 million from EUR13.1 million.

----------

AIM - LOSERS

----------

Pelatro PLC, down 73% at 0.80p, 12-month range 0.69p-24.50p. The marketing software provider decides to cancel shares from AIM market in London, citing costs, management time required, and regulatory burden of maintaining a listing. It will announce schedule for the cancellation, including date of general meeting for shareholders to vote on the plan, "in due course". It will put in place a matched bargain facility to help shareholders buy and sell shares after the delisting. Nic Hellyer resigns as chief financial officer. Leaves board immediately but will remain with company to help with the share cancellation and financial reports. Pelatro says Bangalore-based finance function remains unaffected.

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
4 Jun 2024 11:24

AIM WINNERS & LOSERS: Vast Resources touts progress across mines

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
20 May 2024 09:03

Faron Pharma celebrates positive read-out in ongoing MDS trial

(Alliance News) - Faron Pharmaceuticals Ltd on Monday noted a positive read-out regarding the ongoing Bexmab trial on myelodysplastic syndrome, a form of cancer.

Read more
3 May 2024 13:39

TRADING UPDATES: Kelso raises stake in NCC; Transense joins project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:

Read more
30 Apr 2024 16:33

Faron Pharmaceuticals extends funding agreement with IPF

(Sharecast News) - Faron Pharmaceuticals announced on Tuesday that it has extended its agreement with lender IPF to ensure continued financial support as it progressed towards securing longer-term funding.

Read more
15 Apr 2024 10:58

Faron Pharmaceuticals reappoints former finance chief on interim basis

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it appointed a new interim chief financial officer to replace the outgoing James O'Brien.

Read more
15 Apr 2024 09:36

Faron Pharmaceuticals CFO stands down

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would be leaving the group to "pursue another career opportunity".

Read more
8 Apr 2024 11:50

UPDATE: Faron Pharmaceuticals promotes COO to CEO as father retires

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace his father, the company's founder.

Read more
8 Apr 2024 11:28

Faron Pharmaceuticals promotes COO to CEO as founder steps back

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace the company's founder.

Read more
8 Apr 2024 09:17

Faron Pharmaceuticals taps Juho Jalkanen for CEO

(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.

Read more
4 Apr 2024 11:58

Faron Pharmaceuticals secures funding to deliver next "milestones"

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has successfully raised funds to support the phase two study of its bexmarilimab cancer treatment.

Read more
3 Apr 2024 10:59

TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
2 Apr 2024 13:22

UK shareholder meetings calendar - next 7 days

Wednesday 3 April 
Downing Strategic Micro-Cap Investment Trust PLCGM re approval of B share scheme
Quantum Exponential Group PLCGM re delisting or potential investment in company
Thursday 4 April 
Rio Tinto PLCAGM
Scottish American Investment Co PLCAGM
TheWorks.co.uk PLCGM re Main Market delisting and AIM admission
Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 17:09

LONDON MARKET CLOSE: Stocks downbeat before central bank rate storm

(Alliance News) - Stocks in London closed in the red on Monday, as tech gains in New York failed to make an impact ahead of several interest rate decisions from central banks across the world this week.

Read more
18 Mar 2024 14:14

Faron shares jump on encouraging trial data

(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients who had failed prior hypomethylating agent (HMA) treatment.

Read more
18 Mar 2024 11:41

Faron Pharmaceuticals shares jump on positive data from Bexmab study

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said a study showed more patients responding to treatment in a new readout of the Bexmab study focused on myelodysplastic syndrome, or MDS.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.